Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2019-12-16 16:21:11
Reporting Period:
Accepted Time:
2019-12-16 16:21:11
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1012477 Avadel Pharmaceuticals Plc AVDL Pharmaceutical Preparations (2834) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1600771 L Sandra Hatten C/o Avadel Pharmaceuticals Plc
Block 10-1 Blanchardstown Corp. Park
Dublin L2 15
See Remarks No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Adss Disposition 2019-12-12 3,072 $7.23 55,765 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Adss 3,400 Indirect By Spouse
  1. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.20 to $7.56, inclusive. The reporting person undertakes to provide to Avadel Pharmaceuticals plc, any security holder of Avadel Pharmaceuticals plc, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
  3. The filing of this statement shall not be construed as an admission that the reporting person is, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the beneficial owner of these securities. The reporting person disclaims beneficial ownership of such securities except to the extent of any pecuniary interest therein.